Foyston, Gordon, & Payne Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aon
AON
|
+$11.4M |
| 2 |
PepsiCo
PEP
|
+$6.17M |
| 3 |
Novartis
NVS
|
+$6.03M |
| 4 |
British American Tobacco
BTI
|
+$4.75M |
| 5 |
NVO
Novo Nordisk
NVO
|
+$3.41M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$26.3M |
| 2 |
Microsoft
MSFT
|
+$6.91M |
| 3 |
Bunge Global
BG
|
+$5.72M |
| 4 |
Medtronic
MDT
|
+$5.28M |
| 5 |
Union Pacific
UNP
|
+$4.97M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.36% |
| 2 | Technology | 15.78% |
| 3 | Industrials | 13.89% |
| 4 | Financials | 12.97% |
| 5 | Consumer Staples | 9.8% |
Similar funds
Foyston, Gordon, & Payne's Q4 2016 Portfolio in Review
As of Q4 2016, Foyston, Gordon, & Payne held 78 positions worth $421M, down 19% from $518M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Foyston, Gordon, & Payne withdrew a net $103M in Q4 2016, closing 7 positions and reducing 51 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $26.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 32% a quarter earlier, followed by Technology and Industrials.
Against the trend, Foyston, Gordon, & Payne opened a new position in British American Tobacco worth $4.72M.
- Foyston, Gordon, & Payne's largest Q4 2016 buy was British American Tobacco: 83,820 shares worth $4.72M.
- Foyston, Gordon, & Payne added most to Aon in Q4 2016, an estimated $11.4M increase.
- Foyston, Gordon, & Payne's biggest Q4 2016 reduction was Microsoft, cutting an estimated $6.91M.
- Foyston, Gordon, & Payne fully exited Teva Pharmaceuticals in Q4 2016, selling an estimated $26.3M.
- Foyston, Gordon, & Payne's ten largest holdings make up 40% of its $421M portfolio in Q4 2016.
- Foyston, Gordon, & Payne opened 4 new positions and closed 7 in Q4 2016.
- Foyston, Gordon, & Payne's portfolio value fell 19% quarter-over-quarter to $421M.
Based on Foyston, Gordon, & Payne's 13F filing for Q4 2016, filed 13 Feb 2017.